{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:55Z","timestamp":1744258915436,"version":"3.40.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-11101004"],"award-info":[{"award-number":["NCKUH-11101004"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Plasmablastic lymphoma (PBL), an extremely aggressive B-cell non-Hodgkin lymphoma, is known to be associated with immunosuppression. PBL with primary peritoneal or ovarian involvement is extremely rare. Here, we report a case of PBL in an immunocompetent woman, which involved the right ovary, peritoneum, cervical lymph nodes, and bone marrow.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 42\u00a0year-old immunocompetent premenopausal woman presented with abdominal dullness and distension. Imaging studies revealed the presence of ascites, ovarian mass, peritoneal seedings, and generalized lymphadenopathy. Laparoscopic biopsies of the right adnexal tumor, omental cake, and peritoneal seedings were performed. Poorly differentiated carcinoma was suggested from initial intraoperative frozen sections. The conclusive histological and immunohistochemical diagnosis was however that of PBL. Bone marrow involvement was also confirmed. The patient was treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus daratumumab and bortezomib. Haploidentical peripheral blood stem cell transplantation (halpo-PBSCT) was performed to achieve better disease control. The patient showed sustained partial response for six months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The diagnosis of immunocompetent PBL with intraperitoneal spread before surgery and during intraoperative cryosections remains challenging. Intraperitoneal biopsy and delayed cytoreduction can prevent unnecessary tumor resection. However, a definitive treatment modality is yet to be established. Our patient responded to chemotherapy plus targeted therapy, followed by halpo-PBSCT, leading to a 6-month partial response. Our experience provides additional information on pretreatment evaluation and therapeutic considerations for patients with PBL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-02186-y","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:27:57Z","timestamp":1744147677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasmablastic lymphoma mimicking primary ovarian, tubal or peritoneal cancer: a case report and literature review"],"prefix":"10.1007","volume":"16","author":[{"given":"I-Ning","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Ming","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"Suppl 1","key":"2186_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ijlh.13863","volume":"44","author":"J Bailly","year":"2022","unstructured":"Bailly J, Jenkins N, Chetty D, Mohamed Z, Verburgh ER, Opie JJ. Plasmablastic lymphoma: an update. Int J Lab Hematol. 2022;44(Suppl 1):54\u201363. https:\/\/doi.org\/10.1111\/ijlh.13863. (Erratum in: Int J Lab Hematol. 2022 Dec;44(6):1121).","journal-title":"Int J Lab Hematol"},{"issue":"Suppl 2","key":"2186_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s13224-023-01802-7","volume":"73","author":"S Shruthi","year":"2023","unstructured":"Shruthi S, Kishan Prasad HL, Kanthaje A, Rajendra VKJ. Ovarian plasmablastic lymphoma posing diagnostic dilemma: a rare case report. J Obstet Gynaecol India. 2023;73(Suppl 2):298\u2013300.","journal-title":"J Obstet Gynaecol India"},{"issue":"1","key":"2186_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/ijnm.ijnm_76_22","volume":"38","author":"S Kale","year":"2023","unstructured":"Kale S, Shah S, Purandare N, Puranik A, Agrawal A, Rangarajan V. A rare case of plasmablastic lymphoma of the ovary with synchronous lung malignancy. Indian J Nucl Med. 2023;38(1):71\u20133.","journal-title":"Indian J Nucl Med"},{"issue":"1","key":"2186_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13000-017-0672-x","volume":"12","author":"I Had\u017eisejdi\u0107","year":"2017","unstructured":"Had\u017eisejdi\u0107 I, Babarovi\u0107 E, Vrani\u0107 L, Duleti\u0107 Na\u010dinovi\u0107 A, Lu\u010din K, Kra\u0161evi\u0107 M, et al. Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report. Diagn Pathol. 2017;12(1):83. https:\/\/doi.org\/10.1186\/s13000-017-0672-x.","journal-title":"Diagn Pathol"},{"key":"2186_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218117","author":"SL Guvvala","year":"2017","unstructured":"Guvvala SL, Sakam S, Niazi M, Skaradinskiy Y. Case of primary bilateral diffuse large B-cell lymphoma of the ovary with plasmablastic features in an HIV-negative female patient. BMJ Case Rep. 2017. https:\/\/doi.org\/10.1136\/bcr-2016-218117.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"2186_CR6","first-page":"430","volume":"80","author":"A Avil\u00e9s-Salas","year":"2012","unstructured":"Avil\u00e9s-Salas A, Chanona-Vilchis JG, Candelaria-Hern\u00e1ndez MG, Pe\u00f1a-Torres Mde L, Cu\u00e9llar-Mendoza ME. Presentaci\u00f3n inicial de un linfoma plasmabl\u00e1stico como tumor ov\u00e1rico [plasmoblastic lymphoma initially recognized as ovarian tumor]. Ginecol Obstet Mex. 2012;80(6):430\u20134.","journal-title":"Ginecol Obstet Mex"},{"issue":"16","key":"2186_CR7","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.3390\/jcm11164928","volume":"11","author":"YK Ryu","year":"2022","unstructured":"Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma. J Clin Med. 2022;11(16):4928. https:\/\/doi.org\/10.3390\/jcm11164928.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"2186_CR8","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1182\/blood-2021-150800","volume":"138","author":"EC Ricker","year":"2021","unstructured":"Ricker EC, Ryu YK, Amengual JE. Daratumumab plus chemotherapy induces complete responses in a consecutive series of four patients with plasmablastic lymphoma. Blood. 2021;138(Suppl 1):4573\u20135.","journal-title":"Blood"},{"key":"2186_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","volume":"62","author":"TA Guerrero-Garcia","year":"2017","unstructured":"Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62:12\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2017.09.020.","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"2186_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1182\/blood.V130.Suppl_1.1580.1580","volume":"130","author":"T Guerrero","year":"2017","unstructured":"Guerrero T, Bibas M, Baldini F, Cartron G, Cwynarski K, Dierickx D. Use of bortezomib-containing regimens in the frontline treatment of patients with plasmablastic lymphoma: a multicenter retrospective analysis. Blood. 2017;130(Supplement 1):1580. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1580.1580.","journal-title":"Blood"},{"issue":"10","key":"2186_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncy.22442","volume":"129","author":"LA Julien","year":"2021","unstructured":"Julien LA, Michel RP. Imprint cytology: Invaluable technique to evaluate fresh specimens received in the pathology department for lymphoma workup. Cancer Cytopathol. 2021;129(10):759\u201371. https:\/\/doi.org\/10.1002\/cncy.22442.","journal-title":"Cancer Cytopathol"},{"key":"2186_CR12","unstructured":"National Comprehensive Cancer Network B\u2010Cell Lymphoma (version 1.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 3 April 2024."},{"key":"2186_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980464","volume":"13","author":"C Zeng","year":"2022","unstructured":"Zeng C, Chen Y, Hua J, Liu Y, Cheng TT, Ma X, et al. Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases. Front Immunol. 2022;13: 980464. https:\/\/doi.org\/10.3389\/fimmu.2022.980464.","journal-title":"Front Immunol"},{"key":"2186_CR14","doi-asserted-by":"publisher","first-page":"1354604","DOI":"10.3389\/fimmu.2024.1354604","volume":"15","author":"JW Li","year":"2024","unstructured":"Li JW, Peng HL, Zhou XY, Wang JJ. Plasmablastic lymphoma: current knowledge and future directions. Front Immunol. 2024;15:1354604. https:\/\/doi.org\/10.3389\/fimmu.2024.1354604.","journal-title":"Front Immunol"},{"key":"2186_CR15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","volume":"20","author":"MM Al-Malki","year":"2014","unstructured":"Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic stem cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2186_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-018-4561-9","volume":"18","author":"A Broccoli","year":"2018","unstructured":"Broccoli A, Nanni L, Stefoni V, Agostinelli C, Argnani L, Cavo M, et al. A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer. 2018;18:645.","journal-title":"BMC Cancer"},{"issue":"7","key":"2186_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024498","volume":"100","author":"C Rong","year":"2021","unstructured":"Rong C, Sheng L, Wu A, Sun Y, Ouyang G. Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma: a case report. Medicine (Baltimore). 2021;100(7): e24498.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"2186_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436\u201347.","journal-title":"Ann Oncol"},{"issue":"2","key":"2186_CR19","first-page":"174","volume":"51","author":"FG Rosado","year":"2021","unstructured":"Rosado FG, Coberly J, Gupta A, John G, Naina H, Koduru P, et al. PD1\/PD-L1 expressions in plasmablastic lymphoma with clinicopathological correlation. Ann Clin Lab Sci. 2021;51(2):174\u201381.","journal-title":"Ann Clin Lab Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02186-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:19:54Z","timestamp":1744219194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02186-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02186-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided their written informed consent to participate in this study. The protocol was approved by the National Cheng Kung University Hospital IRB no. B-ER-110-390) in accordance with Declaration of Helsinki, and the laws and regulations of Central Competent Authorities. The consents for stem cell transplantation were obtained from the patient (recipient) and her sibling brother (donor).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}